sTREM2 and GFAP Mediated the Association of IGF-1 Signaling Biomarkers with Alzheimer’s Disease Pathology

Article type: Short Communication

Authors: Wang, Zhe^a | Tan, Lin^a | Zong, Yu^a | Ma, Ya-Hui^a | Wang, Zhi-Bo^a | for the Alzheimer’s Disease Neuroimaging Initiative | Wang, Hui-Fu^{a; b; *} | Tan, Lan^{a; *}

Affiliations: [a] Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China | [b] Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China

Correspondence: [*] Correspondence to: Lan Tan, MD, PhD, Department of Neurology, Qingdao Municipal Hospital, Qingdao University, 5th Donghai Zhong Road, Qingdao, 266000, China. [email protected] and Hui-Fu Wang, MD, PhD, Department of Neurology, Qingdao Municipal Hospital, Qingdao University, 5th Donghai Zhong Road, Qingdao, 266000, China. E-mail: [email protected].

Abstract: Defects in insulin-like growth factor 1 (IGF-1) signaling is a key contributor to Alzheimer’s disease (AD). However, the mechanism of how IGF-1 signaling relates to AD remained unclear. Here, we investigated the association of IGF-1 signaling associated biomarkers with AD pathology, sTREM2, and GFAP. Finally, insulin-like growth factor binding protein 2 (IGFBP-2) was associated with AD pathology, and the association was partly medicated by sTREM2 (Aβ42, β= 0.794, p = 0.016; T-tau, β= 0.291, p < 0.001; P-tau181, β= 0.031, p < 0.001) and GFAP (T-tau, β= 0.427, p < 0.001; P-tau181, β= 0.044, p < 0.001). It suggested that sTREM2 and GFAP mediated the relationship between IGF-1 signaling and AD pathology.

Keywords: AD pathology, Alzheimer’s disease, GFAP, IGF-1 signaling, IGFBP-2, sTREM2

DOI: 10.3233/JAD-220725

Journal: Journal of Alzheimer's Disease, vol. 92, no. 3, pp. 791-797, 2023